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The IL-33/ST2 pathway shapes the regulatory T cell phenotype
to promote intestinal cancer
Eva Pastille1, Marie-Hélène Wasmer2,3, Alexandra Adamczyk1, Vivian P. Vu2,3, Lukas F. Mager4, Nhi Ngo Thi Phuong1, Vittoria Palmieri1,
Cedric Simillion5,6, Wiebke Hansen1, Stefan Kasper7,8, Martin Schuler7,8, Beat Muggli9, Kathy D. McCoy4, Jan Buer1, Inti Zlobec2,
Astrid M. Westendorf1 and Philippe Krebs2
The composition of immune inﬁltrates strongly affects the prognosis of patients with colorectal cancer (CRC). Interleukin (IL)-33 and
regulatory T cells (Tregs) in the tumor microenvironment have been separately implicated in CRC; however their contribution to
intestinal carcinogenesis is still controversial. Here, we reveal that IL-33 signaling promotes CRC by changing the phenotype of
Tregs. In mice with CRC, tumor-inﬁltrating Tregs preferentially upregulate IL-33 receptor (ST2), and IL-33/ST2 signaling positively
correlates with tumor number and size. Transcriptomic and ﬂow cytometry analyses demonstrate that ST2 expression induces a
more activated and migratory phenotype in FOXP3+ Tregs, which favors their accumulation in the tumor environment.
Consequently, genetic ablation of St2 reduces Treg inﬁltration and concomitantly enhances the frequencies of effector CD8+ T cells,
thereby restraining CRC. Mechanistically, IL-33 curtails IL-17 production by FOXP3+ Tregs and inhibits Th17 differentiation. In
humans, numbers of activated ST2-expressing Tregs are increased in blood and tumor lesions of CRC patients, suggesting a similar
mode of regulation. Together, these data indicate a central role of IL-33/ST2 signaling in shaping an immunosuppressive
environment during intestinal tumorigenesis. Blockade of this pathway may provide a strategy to modulate the composition of CRC
immune inﬁltrates.
Mucosal Immunology _#####################_ ; https://doi.org/10.1038/s41385-019-0176-y
INTRODUCTION
Interleukin-33 (IL-33) is an IL-1 family member, which mediates its
biological effects via binding to a heterodimeric receptor complex
formed by IL-1RL1 (or ST2) and its co receptor, IL-1 receptor
accessory protein (IL-1RAP).1 IL-33 is constitutively expressed as a
nuclear factor by a broad range of cell types, including ﬁbroblasts,
epithelial, and endothelial cells, particularly in mucosal tissues.2
However, upon tissue injury, cell stress or necrosis IL-33 can be
released to act as an alarmin by activating cells of lymphoid and
myeloid origin.3
The IL-33/ST2 pathway was originally described to play a key
role in type 2 immunity via activation of ST2-expressing T helper 2
(Th2) cells.4 Besides this Th2-promoting function of IL-33, recent
murine studies provided evidence for a pivotal role of the IL-33/
ST2 pathway on the biology of regulatory T cells (Tregs). More
precisely, in vivo administration of recombinant IL-33 induces a
ST2-dependent proliferation and accumulation of FOXP3+ Tregs in
the thymus and in the periphery. Mechanistically, IL-33 directly
acts on ST2+ FOXP3+ Tregs but also stimulates IL-2 production by
CD11c+ dendritic cells, which in turn facilitate the expansion of
FOXP3+ Tregs.5,6 Furthermore, IL 33 signaling in FOXP3+ Tregs is
important for their stability and suppressive function in vivo.5
Tregs are critical for the maintenance of immune homeostasis
and the prevention of autoimmunity by exerting various
immunosuppressive mechanisms towards self-reactive T cells.7
Conversely, in solid tumors Tregs counteract antitumor immunity.
This explains why high amounts of peripheral or tumor-inﬁltrating
Tregs are often associated with poor prognosis in various cancer
entities.8 However, the role of Tregs for colorectal cancer (CRC) is
ambiguous.
In the intestine, dietary antigens or antigens of commensal
gut bacteria constantly trigger inﬂammatory processes, which
can increase the risk of cancer development if they are not
tightly regulated. By controlling this physiological intestinal
inﬂammation, Tregs maintain immune tolerance, thereby reducing
the risk of inﬂammation-associated tumorigenesis.9 Accordingly,
several studies identiﬁed a positive correlation between high
frequencies of tumor-inﬁltrating FOXP3+ Treg and an improved
survival of CRC patients.10 Nevertheless, FOXP3+ Tregs exert
potent suppressive functions towards effector T cells, thereby
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creating an immunosuppressive environment which may inﬂu-
ence the clinical outcome of CRC patients.11 Such opposing
contribution of Tregs to CRC may rely on the ability of Tregs to
undergo functional plasticity.12 Indeed, Tregs are for instance able
to adapt to the tissue environment and acquire a Th1− or Th17−
effector phenotype while retaining their suppressive function
(reviewed in ref. 13). While the cytokine signals driving T helper cell
differentiation into different subsets are well-characterized, the
nature of the inﬂammatory cues released by the environment to
govern Treg plasticity and function are still elusive.14
During intestinal tumorigenesis, IL-33 protein expression is
induced in transformed epithelial cells.15,16 We previously
reported that IL-33 signaling stimulates the production of pro-
tumorigenic IL-6, and that ST2-deﬁcient mice show a delayed
tumor growth in the colon.16 Several studies support these
ﬁndings of a tumor-promoting role of IL-33/ST2 signaling for
intestinal tumorigenesis, also using different animal models.15,17
However, the identity of the ST2-expressing cells in CRC lesions
and their function during intestinal tumorigenesis is yet to be
clearly deﬁned.
In this study, we investigated the impact of IL-33/ST2 signaling
on immune cell function in CRC. Our ﬁndings using mouse studies
and patient-derived samples indicate that IL-33 critically regulates
the functional phenotype and the number of Treg in the CRC
environment. This in turn restricts effector CD8+ T cell immunity
and promotes tumorigenesis in the colon.
RESULTS
Upregulation of Il33 and St2 expression in murine CRC
IL-33 expression has been shown to become upregulated upon
neoplastic transformation of human and murine colonic tissues
and to promote intestinal tumorigenesis.15,16 To address the role
of the IL-33/ST2 axis on immune cells in CRC, we treated C57BL/6
and BALB/c mice with azoxymethane (AOM)/dextran sulfate
sodium (DSS). Combined application of these chemicals induces
dysplastic changes in the mouse colon that feature many of the
histological and molecular characteristics of human adenocarci-
nomas.18 Independent of the genetic background, we found that
Il33 transcripts and IL-33 protein were increased in malignant
colonic tissues (Fig. 1a, b). Interestingly, colonic Il33 transcripts
were increased as early as 5 weeks after treatment start, with
levels remaining 2.5-fold higher than untreated control mice until
the end of the treatment (Fig. 1c). In addition, expression of both
the soluble (sSt2) and transmembrane forms of St2 (St2) were
upregulated in tumor lesions versus adjacent tumor-free colons of
C57BL/6 mice (Fig. 1d, e).
Tumor-inﬁltrating CD4+ FOXP3+ Tregs preferentially express ST2
IL-33 signals via its unique receptor ST2, which is expressed on
several cell types.3 To identify the cells potentially reacting to IL-33
in the tumor microenvironment, we next measured ST2 expres-
sion on tumor-inﬁltrating immune cells. Compared to untreated
controls, frequencies of ST2-expressing cells in the colon of CRC
mice were higher among T cells and NK cells, yet not among B
cells, granulocytes, macrophages, or dendritic cells. Moreover,
frequencies of ST2-expressing cells remained unchanged among
splenocytes or mesenteric lymph node (mLN) cells of AOM/DSS-
treated mice (Fig. 2a). Tumor-inﬁltrating CD4+ T cells showed the
highest relative ratio of ST2-expressing cells and a substantial
proportion of CD4+ T cells in CRC lesions were FOXP3+ Tregs
(Supplementary Fig. 1A and B). Hence, we further characterized
ST2 expression among CD4+ T cell subsets. Notably, more than
30% of CD4+ FOXP3+ Tregs in colonic tumors of BALB/c mice
expressed ST2, versus 3% of CD4+ FOXP3- T cells (Fig. 2b), thus
indicating that ST2 expression in the CD4+ T cell compartment
was mainly restricted to FOXP3+ Tregs. These ﬁndings were also
validated in C57BL/6 intestinal tumors (Fig. 2c).
We previously demonstrated that CD4+ FOXP3+ Tregs promote
tumor progression in the AOM/DSS-induced model of CRC.19 To
Fig. 1 The IL-33/ST2 pathway is upregulated in intestinal tumors. Mice were treated with AOM/DSS and cancerous colonic tissues (CRC) were
isolated for analysis after 10–12 weeks or at the indicated time points. Unless otherwise indicated, colon tissues from naïve mice of the
corresponding strain were used as control (ctrl). Il33 transcript levels (left panel) and IL-33 protein secretion from explant cultures (right panel)
were measured in the colon of a C57BL/6 mice (n= 6–17 mice per group; data pooled from two, respectively, four independent experiments)
or b BALB/c mice (n= 10–26 mice per group; data pooled from three, respectively, ﬁve independent experiments). c Il-33 transcript levels were
measured in tumor tissues of BALB/c mice at the indicated time points after the ﬁrst AOM injection. Ctrl, n= 21; CRC, n= 3-6 mice per group;
data are from two experiments. Transcript levels of d sSt2 and e St2 were measured in tumor lesions (CRC, n= 8 mice per group) or adjacent
tumor-free tissues (ctrl, n= 7 mice per group) from C57BL/6 mice. Data are from one experiment. Data are mean ± SEM. Statistical analyses
were performed using a, b, d, e standard Student’s t-test or c one-way ANOVA with Dunnett’s post-test. *P < 0.05; **P < 0.01; ***P < 0.001
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address the speciﬁc role of ST2-expressing Tregs in intestinal
tumorigenesis, we next performed a kinetic analysis of colonic
ST2+ CD4+ FOXP3+ Tregs, which were found to progressively
increase in frequency and transiently upregulate the IL-33
receptor during the course of AOM/DSS treatment (Fig. 2d and
Supplementary Fig. 1C, respectively). In addition, the frequency of
CD4+ FOXP3+ Tregs, the proportion of ST2+ CD4+ FOXP3+ Tregs,
and IL-33 protein expression in the colon all positively correlated
with tumor scores (i.e. the sum of the relative size of all tumors in a
given mouse), irrespective of the genetic background (Fig. 2e, f).
Importantly, frequency of ST2+ CD4+ FOXP3+ Tregs—but not of
CD4+ FOXP3+ Tregs—also correlated with intestinal tumorigen-
esis in other murine models of CRC based on mutation in the Apc
gene or on intestinal-speciﬁc deﬁciency in mismatch repair
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(Fig. 2g, h and Supplementary Fig. 1D–G). Together, these data
clearly pointed toward a contribution of IL-33/ST2 signaling to
CRC. Moreover, the gradual upregulation of ST2 on tumor-isolated
CD4+ FOXP3+ Tregs during intestinal tumorigenesis suggested an
immune regulatory function of IL-33 for this disease.
ST2 deﬁciency leads to reduced Treg frequencies in colonic tumor
tissues
To evaluate the role of IL-33/ST2 signaling on CD4+ FOXP3+ Tregs
for intestinal tumorigenesis, we treated C57BL/6 wild-type (WT)
and St2−/− mice with AOM and DSS. Compared to naïve controls,
frequencies of CD4+ T cells were elevated in the CRC tissue,
yet similar between the two groups (Fig. 3a). Importantly,
proportions and absolute numbers of CD4+ FOXP3+ Tregs were
lower in St2−/− versus WT CRC lesions, although ST2 deﬁciency
per se had no impact on Treg ratios in the intestine of naïve mice
(Fig. 3b–d). In line with these results, there were fewer and smaller
intestinal tumors in St2−/− mice, which was further corroborated
by endoscopic analysis and histology (Fig. 3e–g).
Next, we created bone marrow (BM) chimeric mice to assess the
contribution of St2 in the radio-sensitive/hematopoietic compart-
ment to the accumulation of Tregs in CRC. AOM/DSS-treated
chimeras with ST2-deﬁcient hematopoietic cells had no alteration
in CD4+ T cell frequencies, yet they showed a reduction of CD4+
FOXP3+ Tregs in intestinal tumors (Fig. 3h, i).
To also address the speciﬁc contribution of ST2 on CD4+
FOXP3+ Tregs to CRC, we generated mixed BM chimeras by
reconstituting WT recipient mice with equal ratios of BM cells from
WT and Foxp3DTR mice (WT:Foxp3DTR) or from St2−/− and Foxp3DTR
animals (St2−/−:Foxp3DTR). Diphtheria toxin-induced FOXP3+ cell
depletion during colon tumorigenesis in these chimeras provided
a model in which Tregs present in the reconstituted (St2−/−:
Foxp3DTR) animals were the only cell subset being entirely
deﬁcient for ST2, while control (WT: Foxp3DTR) mice harbored
ST2-proﬁcient Tregs (Supplementary Fig. 2A). Longitudinal endo-
scopic studies performed before and after the period of diphtheria
toxin application in these chimeras revealed that presence of ST2-
competent Tregs during CRC development promotes enhanced
tumor formation compared to ST2-deﬁcient Tregs (Supplementary
Fig. 2B). To strengthen these results, St2ﬂ/ﬂ;Foxp3-Cre mice, in
which ST2 is speciﬁcally deleted in Tregs, were next subjected
to AOM/DSS treatment. In line with the data from the BM chimera
experiments, endoscopic analysis after 8 and 10 weeks revealed
fewer and smaller intestinal tumors in St2ﬂ/ﬂ;Foxp3-Cre versus
St2+/+;Foxp3-Cre mice (Fig. 3j). In addition, mice with Treg-speciﬁc
St2 ablation showed delayed tumor progression compared to
controls with ST2-competent Tregs (Fig. 3k).
These results imply that, during DSS/AOM-induced CRC, IL-33/
ST2 signaling is activated in CD4+ FOXP3+ Tregs to promote their
accumulation in the colon. Moreover, the concomitant reduction
in St2−/− mice of tumor load and CD4+ FOXP3+ Tregs and the
ﬁndings that Treg-restricted St2 ablation is associated with
reduced CRC development led us to hypothesize that ST2+
CD4+ FOXP3+ Tregs support CRC development.
Distinct transcriptional proﬁle of ST2-expressing FOXP3+ Tregs in
murine CRC
As frequencies of ST2+ CD4+ FOXP3+ Tregs in CRC tissue
correlated with tumor scores, we next performed a transcriptomic
analysis to better understand the role of ST2 for Treg function
during intestinal tumorigenesis. Principal component analysis
(PCA) of microarray data indicated a clear segregation between
ST2+ and ST2− CD4+ FOXP3+ cells isolated from the colon of
AOM/DSS-treated Foxp3/eGFP reporter mice (Fig. 4a). Moreover,
further analysis showed that multiple pathways were differentially
regulated in ST2+ versus ST2− CD4+ FOXP3+ T cells, in particular
pathways involved in lymphocyte differentiation, regulation, or
migration (Fig. 4b and Supplementary Fig. 3A). Taken together,
these ﬁndings provide evidence that ST2 expression endows
CD4+ FOXP3+ Tregs with distinct phenotypic and possibly
functional features.
ST2 expression modulates the activation but not the suppressive
capacity of Tregs
In the following, we studied potential functional consequences of
the speciﬁc transcription pattern identiﬁed in ST2-expressing
CD4+ FOXP3+ Tregs. First, we compared the capacity of isolated
tumor-inﬁltrating ST2+ versus ST2− CD4+ FOXP3+ Tregs to
suppress CD4+ responder T cells from naive St2−/− donor mice
in vitro. In these settings, ST2 expression did not affect Treg
suppressive activity. However, addition of recombinant murine
IL-33 (rmIL-33) to the culture enhanced the suppressive capacity
of CD4+ FOXP3+ Tregs (Fig. 4c). Next, we applied ﬂow cytometry
analysis for phenotyping. This analysis revealed that, compared to
ST2− counterpart, ST2+ CD4+ FOXP3+ Tregs expressed higher
levels of IKZF2/Helios, thus indicating a more stable regulatory
activity20 and a thymic origin21 (Fig. 4d). The proliferation marker
Ki67 and the inhibitory receptor PD-1 (which is encoded by Pdcd1)
were also upregulated in ST2+ CD4+ FOXP3+ Tregs (Fig. 4e, f).
Moreover, several chemokine receptors including CCR4, CCR5,
CCR9, CXCR3, and the integrins α-E/CD103 and α-V (which are
encoded by Itgae and Itgav, respectively) showed increased
expression on ST2+ versus ST2− CD4+ FOXP3+ Tregs isolated from
CRC lesions (Fig. 4g–l). In agreement with these ﬁndings, the
ligands of these chemokine receptors and integrins were more
abundant in CRC lesions of WT versus St2−/−mice (Supplementary
Fig. 3B–F).
These results supported the notion that ST2+ CD4+ FOXP3+
Tregs are not primarily induced in colonic tumors, but rather
migrate and proliferate at the site of IL-33 expression. Indeed,
detailed analysis of the ontology pathway “leukocyte migration”
indicated several migration-related genes that were differentially
expressed in colonic ST2+ versus ST2− CD4+ FOXP3+ Tregs. In
particular, endothelin receptor type B (Ednrb), Ccr1, Gpr15, myosin
Fig. 2 ST2 is preferentially upregulated on CD4+ FOXP3+ Tregs in intestinal tumors. Mice were treated with AOM/DSS (CRC; black bars) or left
untreated (ctrl; white bars), and immune cells from spleen, mesenteric lymph nodes (mLN), or colon were analyzed by ﬂow cytometry.
a Frequencies of ST2-positive cells were measured among CD4+ T cells, CD8+ T cells, B220+ B cells, GR1+ granulocytes, F4/80+ CD11cint/−
macrophages (Mph), CD11c+F4/80− dendritic cells (DC) and CD335+ NK cells, respectively (n= 7–8 BALB/c mice per group). Frequencies of
ST2-positive cells were measured among FOXP3− (left panel) or FOXP3+ (right panel) CD4+ T cells from b BALB/c (n= 15–22 mice per group)
or c C57BL/6-Foxp3/RFP mice (n= 10–16 mice per group). d Frequencies of ST2+ FOXP3+ Tregs were measured in CRC lesions of BALB/c mice
at the indicated time points during AOM/DSS treatment (n= 26 for ctrl and n= 7–11 for CRC mice per time point). FOXP3+ Treg frequencies
(left panel), ST2-expressing FOXP3+ Treg frequencies (middle panel), or IL-33 protein expression (right panel) in colon were correlated with
tumor score in e BALB/c (n= 16-28) or f C57BL/6-Foxp3/RFP (n= 14–31) mice. g Alternatively, Apc+/1638N mice (n= 13) were analyzed at
different ages and frequencies of ST2-expressing FOXP3+ Treg were correlated with tumor numbers in the colon. h Msh2ﬂ/ﬂ;Villin-Cre mice (n=
11) were analyzed 269–342 days after birth and frequencies of ST2-expressing FOXP3+ Treg were correlated with tumor weight in the small
intestine. Data are mean ± SEM and were pooled from a, h two, b, c four, d three, e 4–5, f 3–7 or g several independent experiments. Statistical
analyses were performed using a–c two-way ANOVA with Sidak post-test and d one-way ANOVA with Dunnett's post-test. Correlations were
calculated using Spearman correlation analysis. *P < 0.05; **P < 0.01; ***P < 0.001
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1G (Myo1g), and integrin α-9 (Itga9) were upregulated in ST2+
CD4+ FOXP3+ Tregs (Fig. 4m). These genes or the ligands of their
products have been involved in intestinal inﬂammation or CRC
development,22–26 which suggests an active migration of ST2+
Tregs to the tumor tissue.
IL-33 restrains IL-17 production in CD4+ T cells
FOXP3+ Tregs exhibit phenotypic plasticity and provide a source
of IL-17 in CRC.27 IL-17 contributes to intestinal tumorigenesis in
mice since genetic ablation of Il17a leads to decreased AOM/DSS-
induced CRC.28 Our transcriptomic analysis revealed that genes
from the ontology pathway “Th17 cell differentiation” were
differentially expressed in ST2+ versus ST2− tumor-derived CD4+
FOXP3+ T cells (Fig. 4b and Supplementary Table 1). More
precisely, Il6ra, Rorc, and Il1r1 were downregulated in ST2+ CD4+
FOXP3+ Tregs (Fig. 5a), pointing towards an impaired ability to
convert into IL-17-expressing cells. Congruent with these ﬁndings,
IL-17 protein in CRC lesions was detected in ST2− Tregs or CD4+
effector T cells, but not in ST2+ Tregs (Fig. 5b, c).
To further investigate whether IL-33 signaling may affect the
ability of FOXP3+ Tregs to produce IL-17, we cultured CD4+
FOXP3+ T cells from naïve Foxp3/eGFP mice under Th17-polarizing
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conditions, with or without rmIL-33. Besides increasing ST2
expression, IL-33 inhibited the expression of IL-17A in CD4+
FOXP3+ Tregs (Fig. 5d, e). To assess whether IL-33 may also affect
IL-17 expression of in vitro-induced Th17 cells, naïve CD4+
FOXP3− T cells were in vitro differentiated into Th17 cells in the
presence or absence of rmIL-33. Interestingly, Th17-polarizing
conditions promoted the generation of IL-17A-producing CD4+
FOXP3+ Tregs, which was impaired upon addition of rmIL-33
(Fig. 5f, g). Furthermore, IL-33 signaling also reduced the
proportion of IL-17A-expressing FOXP3− (conventional) CD4+
T cells among Th17-polarized cells (Fig. 5h). These results are in
agreement with our previous data indicating increased Il17a
transcript levels in CRC lesions of St2−/− versus WT mice (mean
relative expression: 2.99 × 10−2 ± 9.25 × 10−3 versus 3.98 × 10−4 ±
1.44 × 10−4, P < 0.01; n= 9 and 8, respectively).16 Therefore, IL-33
appears to restrain the conversion of CD4+ T cells into IL-17-
producing cells, also during intestinal tumorigenesis.
ST2 deﬁciency promotes CD8+ T cell effector function and leads to
improved tumor control in AOM/DSS-treated mice
Using the AOM/DSS-induced model of CRC, we previously demon-
strated that cytotoxic CD8+ T cells critically participate in antitumor
immunity, and that ablation of FOXP3+ Tregs during intestinal
tumorigenesis results in an increase of effector CD8+ T cells in the
colon.19 Remarkably, we found a negative correlation between the
frequency of ST2+ CD4+ FOXP3+ T cells and the frequency of CD8+
T cells in AOM/DSS-induced CRC lesions, thereby suggesting that
IL-33/ST2 signaling adversely affects CD8+ T cell immunity during
CRC (Fig. 6a). Indeed, there was a higher proportion of CD8+ T cells
in the colon of AOM/DSS-treated St2−/− compared to WT mice
(Fig. 6b). Furthermore, frequencies of IFNγ-expressing CD8+ T cells
(Fig. 6c, d) and GZMB production in CD8+ T cells (Fig. 6c, e, f) were
increased in St2−/− versus WT CRC tissue.
Together, these results suggested that AOM/DSS-treated St2−/−
mice develop smaller CRC tumors compared to WT controls
because of improved cytotoxic CD8+ T cell immunity in their
colon. To address this possibility, we induced CRC in St2−/− and
WT mice and depleted CD8+ T cells by repetitively injecting anti-
CD8 antibody after the last cycle of DSS (Fig. 6g). As expected, WT
mice depleted of CD8+ T cells showed a tendency to higher tumor
scores than CD8+ T cell-replete counterparts 63 days after
treatment start (P= 0.0546). Importantly, long-term depletion of
CD8+ T cells also triggered tumorigenesis in St2−/− mice, to tumor
scores comparable to the ones in non-depleted control WT mice
(Fig. 6h).
Therefore, we conclude that IL-33/ST2 signaling on CD4+
FOXP3+ Tregs acts to restrain CD8+ T cell-mediated immune
surveillance in the AOM/DSS model of CRC.
Increased presence of ST2+ FOXP3+ Tregs in the blood and
tumors of CRC patients
To address the general relevance of our ﬁndings from murine
studies, we next assessed ST2 expression in FOXP3+ Tregs from
blood and colon of CRC patients. Compared to healthy donors, we
found increased proportions of CD4+ FOXP3+ T cells and ST2-
positive Tregs in peripheral blood mononuclear cells (PBMCs) of
CRC patients (Fig. 7a, b). In agreement with our mouse data, the
migration markers CXCR3 and CCR5 were more frequently
expressed on circulating ST2+ versus ST2− CD4+ FOXP3+ Tregs
from CRC subjects (Fig. 7c, d).
We next studied the immune cell inﬁltrate of resected colon
cancers. Compared to adjacent tumor-free colon, CD4+ FOXP3+
T cells and ST2-positive Tregs were more abundant in human CRC
lesions, yet ST2 expression levels were unchanged in tumor tissue
(Fig. 7e–g). There were also more ITGAE (CD103)-expressing and
CXCR3-expressing ST2+ Tregs in CRC than in adjacent tumor-free
colon (Fig. 7h, i). Further studies using immunoﬂuorescence
conﬁrmed the presence of ST2+ FOXP3+ cells in human intestinal
tumors. Moreover, these FOXP3+ lymphocytes were located in the
vicinity of IL-33-expressing tumor cells (Fig. 7j, k).
These ﬁndings extend our in vivo data in mice and substantiate
their relevance for the human intestine. Moreover, they suggest
that the IL-33/ST2 pathway acts on CD4+ FOXP3+ Tregs also in
human CRC.
DISCUSSION
The tumor microenvironment has lately emerged as a major
contributor to tumorigenesis, by providing either proliferative or
inhibitory signals to the malignant cells.29 This is especially true for
CRC, whose progression is substantially affected by cytokines and
inﬂammatory mediators released in the tumor milieu.30,31 As an
alarmin preferentially expressed in epithelial cells at barrier sites,
and because of its role in intestinal disorders, IL-33 has recently
gained particular attention for its contribution to CRC. However,
while most reports describe a pro-tumorigenic effect of IL-33 in the
intestine, several studies suggest the opposite (reviewed in refs. 3,32).
Moreover, the functional role of IL-33 on ST2-expressing cells in the
microenvironment of CRC has remained largely elusive.32
Here, we present evidence that IL-33/ST2 signaling shapes the
phenotype of Tregs to promote intestinal tumorigenesis. Indeed,
our data show that ST2-expressing Tregs preferentially accumulate
in CRC lesions, and these cells are phenotypically distinct from
ST2-negative counterparts. This leads to a restrained CD8+ T cell-
mediated tumor immune surveillance, and thus an enhancement
of intestinal tumorigenesis. In addition, we found that the IL-33/
ST2 pathway suppresses IL-17 production and thereby modiﬁes
the inﬂammatory signals within the tumor microenvironment.
Tregs limit overt inﬂammatory responses to maintain intestinal
immune homeostasis. However, the role of Tregs in CRC remains
controversial. As a matter of fact, Treg suppressive activity may
produce dual effects on inﬂammation-associated cancers, such as
CRC, and tumor-inﬁltrating Tregs may correlate with either better
or worse prognosis of patients with intestinal tumors (reviewed in
ref. 33). In mice, Treg depletion during the early phase of the AOM/
DSS treatment exacerbates the intestinal inﬂammation, leading to
Fig. 3 Treg frequencies are reduced in tumors of St2−/−mice. Wild-type (WT) or St2−/− C57BL/6 mice were treated with AOM/DSS (CRC) or left
untreated (ctrl) and a frequencies of CD4+ T cells in colonic tissues were measured after 10 weeks (n= 4–20 mice per group). b Flow
cytometry plots from one representative CRC mouse per group depicted in c showing frequencies of CD4+ FOXP3+ Tregs (panels on the left)
and frequencies of ST2-expressing cells among FOXP3+ Tregs (panels on the right). c Frequencies of FOXP3+ Treg were measured among
CD4+ T cells based on the gating strategy shown in b. d Absolute numbers of FOXP3+ Treg were measured in the colon of AOM/DSS-treated
mice (n= 8–9 mice per group). e Tumor numbers and tumor load were assessed in the colon of CRC mice (n= 5 mice per group). f Endoscopy
pictures showing tumors in the distal colon from one representative CRC mouse per group depicted in e. g Hematoxylin and eosin (H&E)
sections displaying representative colon tumors in the indicated groups of mice. Scale bars: overview: 200 μm; inlay: 100 μm. Indicated sets of
chimeric mice were treated with AOM/DSS and h frequencies of CD4+ T cells or i frequencies of CD4+ FOXP3+ Treg were measured in the
indicated organs after 10–13 weeks (n= 7–8 mice per group). j Intestinal tumorigenesis was assessed by endoscopy and k tumor
development was calculated in the indicated groups of mice by subtracting tumor score on week 10 from tumor score on week 8 after the
start of AOM/DSS treatment (n= 8–9 mice per group). Data are mean ± SEM and show a, c four pooled independent experiments out of six or
e one representative experiment out of three. d, h, i, k data were pooled from two independent experiments. Statistical analyses were
performed using a, c–e, k standard Student’s t-test or h, i one-way ANOVA with Bonferroni post-test. *P < 0.05; **P < 0.01; ****P < 0.0001
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decreased survival. In contrast, Treg depletion at later stages curbs
tumorigenesis.19
In human CRC lesions, ST2 protein is expressed not only on
normal and transformed epithelial cells, but also on endothelial
cells, myoﬁbroblasts, and inﬁltrating immune cells.15,16 Indeed, our
previous ﬁndings from studies with BM chimeric mice indicate
that both radio-resistant and hematopoietic cells engage the
IL-33/ST2 pathway to drive tumorigenesis in the colon, thereby
decreasing the intestinal barrier and inducing protumorigenic
cytokines.16 In murine adenomatous polyps, ST2-positive sub-
epithelial myoﬁbroblasts and mast cells react to IL-33 by secreting
extracellular matrix components, proteases, and growth factors
associated with intestinal tumor progression.15 Dissection of
immune populations in AOM/DSS-treated mice revealed FOXP3+
Tregs to be the preponderant type of ST2-positive cells in CRC
lesions. Moreover, we found that frequencies of ST2+ Tregs
gradually increase during CRC development to correlate with
tumor scores and IL-33 expression. Inversely, lower Treg propor-
tions in intestinal tumors of St2−/− mice are associated with
reduced CRC development. Importantly, kinetic analysis indicated
that ST2+ Tregs accumulate in tumors, particularly at later stages
of AOM/DSS-dependent CRC. A possible involvement of ST2-
expressing Tregs in human cancer has not been investigated so
far. Here, we establish that circulating FOXP3+ Tregs from patients
with intestinal cancer upregulate ST2, and that ST2+ FOXP3+
Tregs show preferential accumulation in tumor versus non-tumor
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colonic tissues. These ﬁndings further validate the pertinence
of our observations from mouse studies. Together, our results
suggest that ST2-expressing Tregs precipitate intestinal
tumorigenesis.
Of note, another study recently reported an anti-tumoral effect
of the IL-33/ST2 pathway on the development of sporadic CRC,
with an increased frequency of tumor-inﬁltrating FOXP3+ Tregs
in BM chimeric mice lacking ST2 expression on both the
hematopoietic and the radio-resistant compartments.34 These
differences with our investigation may rely on the type of CRC
model applied—AOM only versus AOM and DSS treatment—or
the genetic background of the St2−/− mice used—BALB/c versus
C57BL/6J. Nevertheless, our data indicate that ST2+ CD4+ FOXP3+
Tregs may also promote tumorigenesis in other murine models of
CRC based on genetic ablation of tumor suppressor genes
critically regulating intestinal cancer.
Importantly, our data indicate that CRC-derived Tregs display a
distinct phenotype when expressing ST2. Indeed, compared to
ST2− counterparts, ST2+ Tregs in human and mouse CRC exhibit
increased expression of integrins and several chemokine recep-
tors. Some of these molecules like CXCR3, CCR5, CCR9, and GPR15
have been involved in gut homing, trafﬁcking to, or retention in
the intestine.35–38 CCR5, which we found to be more present on
circulating ST2+ versus ST2− Tregs in intestinal cancer patients,
has been implicated in the recruitment of Tregs to solid murine
tumors, including CRC.39 Moreover, there is evidence for a
potential involvement of IL-33 in immune cell chemotaxis.40 Of
note, ST2+ Tregs have been previously described to preferentially
home outside of secondary lymphoid organs, especially to the
lung, but also to the intestine, at steady-state.41 Taken together,
these data strongly suggest that IL-33/ST2 signaling promotes the
accumulation of Tregs to CRC lesions by modulating their
migratory or tissue-retention properties.
Our ﬁndings from in vitro functional studies and from
transcriptomic analyses of tumor tissues and CRC-isolated Tregs
also indicate an implication of the IL-33/ST2 axis in the regulation
of IL-17A expression by FOXP3+ Tregs and FOXP3− CD4+ T cells.
Indeed, our data support the notion that IL-33/ST2 signaling
constrains IL-17A production while it favors the generation of IL-
17-negative ST2+ FOXP3+ Tregs. Tregs represent a heterogeneous
population comprising a minor subpopulation with developmen-
tal plasticity.42 As a matter of fact, human and murine Tregs in CRC
lesions may also produce IL-17. These IL-17+ FOXP3+ Tregs
express RORγt and exert immunosuppressive function, yet they
display compromised anti-inﬂammatory properties and are
pathogenic in the context of CRC.27 Interestingly, in mice
challenged with ovarian cancer or CRC cells, Th17 (IL-17A+
FOXP3−) and IL-17A+ FOXP3+ cells can transdifferentiate into
IL-17A-negative CD4+ FOXP3+ T cells with immunosuppressive
function. Moreover, transcriptomic analysis and ﬂow cytometry of
IL-17A+ FOXP3+ cells indicated ST2 as one of the markers of this
Th17-to-Treg cell conversion.43 Our ﬁndings of increased Il17a
transcript levels in tumors of St2−/− mice are also in line with the
previous observation that absence of ST2-mediated signaling
favors the expansion of IL-17-producing Th17 cells in the small
intestine of mice treated with anti-CD3 antibody.44
Therefore, we propose that the IL-33/ST2 axis regulates T cell
plasticity in CRC tissue, by stabilizing the phenotype of IL-17-
negative FOXP3+ Tregs and potentially promoting the conversion
of IL-17-producing CD4+ T cell types to these IL-17-negative
(RORγt−) FOXP3+ Tregs. Yet, additional studies are warranted to
deﬁnitively address the function of IL-33/ST2 signaling for CD4+
T cell plasticity in the intestinal tumor environment. Furthermore,
given the dual, context-dependent effect of IL-17-producing CD4+
T cell types in CRC,27,45 it will be also relevant to further investigate
the relative contribution of the IL-33 and IL-17 pathways to
intestinal tumorigenesis.
Tregs impair tumor rejection by suppressing the cytotoxicity of
tumor-speciﬁc CD8+ T cells.46 Consequently, Treg depletion leads
to intratumoral accumulation of activated cytotoxic CD8+ T cells
and tumor regression.19 In AOM/DSS-treated mice, these cytotoxic
CD8+ T cells directly control CRC development.19 Although ST2
expression has been associated with an activated phenotype and
an improved capacity of Tregs to restrain T cell proliferation
in vitro,41 we did not detect difference in the suppressive function
of ST2+ versus ST2− Tregs in our model. This suggests that lower
tumor Treg frequencies and numbers—rather than altered Treg
suppression—underlie the higher proportion of activated cyto-
toxic CD8+ T cells found in CRC lesions of St2−/− versus WT mice.
Nevertheless, our data establish that CRC-derived ST2+ Tregs are
transcriptionally distinct from their ST2− counterparts, as they also
show increased surface expression of PD-1, a molecule involved in
Treg development, function, and stability.47
In conclusion, our ﬁndings indicate that IL-33/ST2 signaling
shapes the cellular and the inﬂammatory composition of the
tumor microenvironment to promote intestinal tumorigenesis.
They also delineate the complexity of the interactions between
the different immune cell types in the cancer stroma, and indicate
that strategies for CRC treatment should best be designed to
target multiple rather than single inﬂammatory pathways for
therapeutic blockade.
METHODS
Mice
All animal experiments at the University of Bern were performed
in accordance with the Swiss Federal regulations and were
approved by the Cantonal Veterinary Ofﬁce. Mice strains used in
Fig. 4 ST2 expression shapes the transcriptome and the phenotype of tumor-derived FOXP3+ Tregs. Foxp3/eGFP mice were treated with
AOM/DSS and eGFP+ CD4+ T cells from CRC lesions were sort-puriﬁed into ST2+ versus ST2− cells for microarray analysis. a Principal
component analysis depicting matched samples, connected by lines, from four analyzed mice. b Pathway analysis showing 58 pathways that
were found to be differentially regulated between ST2+ versus ST2− eGFP+ CD4+ T cells (with adjusted p-value p < 0.001 and corrected
p-value p < 0.001). Graph key: red color indicates increased signiﬁcance and blue (purple) no signiﬁcance. Size of circles is proportional to the
number of genes within a pathway. Connection lines indicate pathways that share genes. Thickness of connecting lines is proportional to the
number of genes shared between two pathways. Double lines indicate that the intersection between two pathways is signiﬁcant. Dotted
arrow lines indicate that a particular pathway corresponds to a subset within another pathway. Line length has no particular meaning. Full
pathway names, detailed results, and references for the different pathways are shown in Supplementary Table 1. c To assess their suppressive
capability, sort-puriﬁed ST2− and ST2+ eGFP+ Tregs were co-cultured at a 1:2 ratio with anti-CD3-activated responder St2−/− T cells (Tresp),
together with St2−/− antigen-presenting cells, in the presence or absence of IL-33. Proliferation of Tresp was analyzed after 3 days, based on
the extent of eFluor670 ﬂuorescence dilution. Histograms show one representative out of three independent experiments. d–l ST2− and ST2+
Tregs (deﬁned as CD4+ FOXP3+ T cells) were analyzed for expression of the indicated markers (n= 7–15 mice per group, pooled from 2 to 3
independent experiments). m Heat map showing all genes in the gene ontology pathway “leukocyte migration” (GO:0050900) that are
differentially expressed in ST2+ versus ST2− eGFP+ Tregs isolated from CRC lesions from the indicated four mice (adjusted p-value p ≤ 0.05).
Blue indicates higher transcript expression in ST2– Tregs and red higher expression in ST2+ Tregs. d–l Data are mean ± SEM and statistical
analyses were performed using paired Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001
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Bern were all on C57BL/6 genetic background. All animal
experiments in Essen were performed in accordance with the
ethical principles and guidelines for scientiﬁc experiments and
were approved by the local Landesamt für Natur-, Umwelt- und
Verbraucherschutz (LANUV, North-Rhine-Westphalia, Germany).
Mice strains used in Essen were either on a BALB/c or on a
C57BL/6 genetic background.
Il1rl1tm1Anjm (Il1rl1−/− or St2−/−) mice were previously
described48 and backcrossed on a C57BL/6J background. C57BL/
6J and C57BL/6-Foxp3tm1Flv/J (termed Foxp3/RFP; JAX stock
#008374) mice were purchased from Jackson Laboratories and
subsequently bred in house.
St2ﬂ/ﬂ;Foxp3-Cre mice, with Treg-speciﬁc St2 deletion, were
generated by crossing Il1rl1tm1c(KOMP)Wtsi (www.komp.org)49 with
Foxp3tm1(cre)Saka50 mice. B6.129(Cg)-Foxp3tm3(DTR/GFP)Ayr/J (Foxp3DTR
mice) are commercially available and have been previously
described.51 For chimera experiments, homozygous female
Foxp3DTR mice were used as BM donors. BALB/c mice were
purchased from Envigo (Borchen, Germany). Il1rl1tm1Aki (termed
St2−/−) and C.Cg-Foxp3tm2Tch/J (termed Foxp3/eGFP)52 mice on a
BALB/c background were bred and housed at the local animal
facility of the University Hospital Essen.
For all experiments, non-randomized groups of 6–9-week-old
animals were either co-housed (for females) or soiled bedding was
Fig. 5 IL-33 restrains IL-17 production in CD4+ T cells. a Foxp3/eGFP mice were treated with AOM/DSS and eGFP+ CD4+ T cells were isolated
from CRC lesions for transcriptomic analysis. Heat map showing all genes in the gene ontology pathway “Th17 cell differentiation” (ko04659)
that are differentially expressed in ST2+ versus ST2− eGFP+ Tregs isolated from CRC lesions from the indicated four mice (adjusted p-value p ≤
0.05). Blue indicates higher transcript expression in ST2− Tregs and yellow/red higher expression in ST2+ Tregs. BALB/c mice were treated with
AOM/DSS and FOXP3− CD4+ T cells b or FOXP3+ CD4+ Tregs c were analyzed in the intestine for ST2 and IL-17 expression. Shown are ﬂow
cytometry plots from each one representative sample out of three. d–h Sort-puriﬁed eGFP+ b, c or eGFP− d, f CD4+ T cells from spleens of
naïve Foxp3/eGFP reporter mice were stimulated with anti-CD3/anti-CD28 antibodies (ctrl) or cultured under Th17 polarizing conditions in the
presence or absence of IL-33. d Frequencies of ST2-positive or e IL-17A-positive cells were measured among CD4+ FOXP3+ Tregs. f Flow
cytometry plots from one representative experiment showing the gating strategy applied to assess the proportion of IL-17A-expressing cells
among FOXP3+ (right upper panel) or FOXP3- CD4+ T cells (right lower panel). In this particular dataset, eGFP− CD4+ T were cultured under
Th17-polarizing conditions, in the presence of IL-33. Frequencies of IL-17A-expressing cells were measured among g CD4+ FOXP3+ Tregs or
FOXP3− CD4+ T cells h. d, e Data are mean ± SEM and were pooled from two representative experiment (n= 6 mice). Statistical analyses were
performed using paired Student’s t-test. g, h Data are mean ± SEM (n= 10 mice, pooled from three independent experiments) and statistical
analyses were performed using Wilcoxon matched-pairs signed rank test. *P < 0.05; **P < 0.01
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exchanged weekly (for males), 2 weeks prior to and during
experiments.
Apctm1Rak (Apc+/1638N) mice have been previoulsy described53
and were bred at the University of Bern. Msh2tm2.1Rak × B6.SJL-Tg
(Vil-cre)997Gum/J (Msh2ﬂ/ﬂ;Villin-Cre) animals,54 with conditional
inactivation of Msh2 in intestinal epithelial cells, were kindly
provided by Dr. Kevin Haigis and Dr. Winfried Edelman and
analyzed in Calgary. Experiments with Msh2ﬂ/ﬂ;Villin-Cre mice were
performed in accordance with the ethical laws of Alberta/Canada
and with protocols approved by the Health Sciences Animal Care
Committee (protocol Number AC17-0090), following the guide-
lines from the Canadian Council for Animal Care.
Generation of and experiments using BM chimeras
Recipient mice were irradiated twice with a dose of 650 cGy each
after a recovery time of 4 h in between. Mice were then adoptively
transfused with 2–5 × 106 whole BM cells from donor mice,
injected i.v., and antibiotic-treated with Bactrim (Roche) and
Baytril (Bayer) in the drinking water for 2 weeks. Following
antibiotic treatment, recipient mice were co-housed (for females)
Fig. 6 Increased frequencies of effector CD8+ T cells in CRC lesions of St2−/− mice lead to improved antitumor immunity. Mice were treated
with AOM/DSS and immune cells were analyzed in CRC lesions (CRC) or in adjacent tumor-free colons (ctrl). a Frequencies of CD8+ T cells were
correlated with frequencies of ST2+ CD4+ Tregs in WT tumor tissues (n= 47 mice, pooled from nine independent experiments). b Frequencies
of CD8+ T cells were measured in the intestine of the indicated strains. c Flow cytometry plots from one representative mouse per group
depicted in d or e showing CRC-derived CD8+ T cells expressing IFNγ or GZMB, respectively. d Frequencies of IFNγ– or e GZMB-expressing
CD8+ T cells were measured in the intestine of the indicated strains. f Median ﬂuorescence intensity (MFI) of GZMB was measured on CRC-
derived CD8+ T cells. g Mice were treated with AOM/DSS with or without antibody-mediated CD8+ T cell depletion, as shown in this
experimental setup; h colonoscopy was then performed for longitudinal assessment of the tumor score in the indicated groups, at the
indicated time points after the ﬁrst AOM injection. Data are mean ± SEM. Data in b–f depict one representative out of six independent
experiments (n= 4–5 mice per group) and data in h show one out of two experiments. Correlation in a was performed using Spearman
correlation analysis and statistical analyses were performed using b–f standard Student’s t-test or h two-way ANOVA followed by uncorrected
Fisher's LSD test. Statistics in h are shown only for the last colonoscopy time point. *P < 0.05; **P < 0.01; ***P < 0.001
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or soiled bedding was exchanged with untreated mice for 2 weeks
prior to the AOM/DSS treatment to ensure a faster re-colonization
of the intestinal ﬂora of the BM recipient mice. AOM/DSS
treatment of chimeras was initiated 6–8 weeks after BM
reconstitution.
Induction and assessment of intestinal tumors in mice
Intestinal tumors were induced by treating mice with AOM (Sigma,
A5486) and DSS (MP Biomedicals, 0216011090), as previously
described.16,19 Seven days after intraperitoneal AOM injection
(10–12.5 mg/kg of body weight), mice were given 1–3% DSS in the
drinking water for 5 days, followed by 7 days of water. Mice then
received a second injection of AOM, which were followed by two
cycles of 1–3% DSS and water. Starting 6 weeks after the ﬁrst
injection of AOM, colonoscopy was performed at different
time points to evaluate tumor development in the distal part of
the colon and to determine tumor scores. In brief, mice were
anesthetized with isoﬂurane, a rigid miniature endoscope was
Fig. 7 Increased presence of ST2+ FOXP3+ Tregs in the PBMCs and tumors of CRC patients. CD4+ FOXP3+ Tregs were analyzed in PBMCs from
healthy controls (ctrl) and CRC patients to measure a cell frequencies and b proportions of ST2-expressing cells (ctrl, n= 13; CRC, n= 15).
c Frequencies of CXCR3-expressing (n= 15) or d CCR5-expressing cells were quantiﬁed among circulating ST2-negative versus ST2-positive
CD4+ FOXP3+ Tregs from CRC patients (n= 10). Alternatively, lymphocytes were isolated from tumor (CRC) versus adjacent tumor-free (ctrl)
colons and e numbers of CD4+ FOXP3+ Tregs (ctrl, n= 18; CRC, n= 23) and of f ST2+ Tregs (ctrl, n= 14; CRC, n= 21) were determined per
gram of tissue. g Representative histograms showing ST2 expression on CD4+ FOXP3+ Tregs from tumor versus adjacent tumor-free
colons from two CRC patients. Numbers of intestinal CD4+ FOXP3+ Tregs were determined for h CD103+ (ctrl, n= 7; CRC, n= 12) or (i) CXCR3+
(ctrl, n= 8; CRC, n= 12) cells. j Immunoﬂuorescence was performed on human CRC tissue for DAPI (blue), FOXP3 (red), and ST2 (green). Scale
bars: 10 µm. k Representative immunohistochemistry of human CRC tissue showing FOXP3-expressing lymphocytes (red) in the vicinity of
IL-33-positive transformed intestinal epithelial cells (brown). Image magniﬁcation is indicated. Scale bars: 100 and 50 µm, respectively. Data are
mean ± SEM. Statistical analyses were performed using a, b Mann–Whitney test, c, d paired Student’s t-test, e, f, h, i Wilcoxon matched-pairs
signed-rank test. *P < 0.05; **P < 0.01; ***P < 0.001
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inserted into the colon for visualization of the intestinal tissue.
Tumor size and numbers were assessed from the digital video
recording of the endoscopic procedure and tumor sizes were
graded as follows; size grade 1: very small but detectable tumors;
size grade 2: tumor covering up to one-eighth of the colonic
circumference; size grade 3: tumor covering up to one-fourth of
the colonic circumference; size grade 4: tumor covering up to half
of the colonic circumference; and size grade 5: tumor covering
more than half of the colonic circumference. Tumor scores were
then calculated for each mouse by adding tumor numbers and the
size grades of all tumors.
Tumor load for each mouse was determined by adding the
volume of each tumor, which was measured with a pair of sliding
calipers and calculated as (W × L × H)×π/6, as previously
described.16 Mice were sacriﬁced for ﬁnal analysis 10–12 weeks
after the ﬁrst AOM injection.
Tumors in Msh2ﬂ/ﬂ;Villin-Cre were weighed using a ﬁne scale
(Mettler Toledo).
In vivo cell depletion
For the depletion of FOXP3+ Tregs from Foxp3DTR immune cells,
mice were injected i.p. with diphtheria toxin (DT; Sigma-Aldrich,
30 ng/g of body weight) twice a week, for 2.5 weeks.
For depletion of CD8+ T cells, mice were injected i.p. with 250
µg of anti-mouse CD8 antibody (Bio X cell, clone YTS 169.4), twice
a week, for 5 weeks.
Isolation of immune cells from murine BM and intestinal tissue
For the isolation of immune cells from BM, femurs were ﬂushed
with DMEM containing 10% FCS. Cells were then centrifuged and
ﬁltered through a 70 µm cell strainer (BD Biosciences, San Jose, CA).
For the isolation of immune cells from the murine intestine,
colons were ﬂushed with PBS to remove feces and then
longitudinally sectioned. Murine colonic tissues were cut into 1
cm pieces and washed by rotation twice for 10min at 37 °C with
PBS containing 3mmol/l EDTA. Tissues were then washed by
rotation twice for 15min at 37 °C with RPMI-1640 containing 1%
FCS, 1 mmol/l EGTA and 1.5 mmol/l MgCl2. Tissues were subse-
quently rinsed with PBS, further minced and digested for 60 min at
37 °C in RPMI-1640 medium containing 20% FCS and 100 U/ml
collagenase IV (Sigma-Aldrich). After digestion, single cells were
separated from the remaining tissue using a 40 µm cell strainer
and washed with RPMI-1640 before further use.
For the isolation of lymphocytes from freshly resected intestinal
tumor or tumor-free tissues from CRC patients, the same protocol
was used as for murine tissues. All human CRC tissues were
provided by the Tissue Bank Bern.
Flow cytometry
Blood-isolated or tissue-isolated leukocytes were stained using the
marker-speciﬁc ﬂuorochrome-labeled antibodies indicated in
Supplementary Table 2. For intracellular detection of proteins,
including FOXP3 (murine and human), IL-17A, Helios, Ki67, and
GZMB, a FOXP3 Transcription Factor Staining Buffer Kit was used
(ThermoFisher). For the assessment of intracellular IL-17A or IFNγ,
cells were stimulated with 1 µg/ml ionomycin and 10 ng/ml
phorbol 12-myristate 13-acetate (PMA) in the presence of 5 µg/ml
Brefeldin A (all Sigma-Aldrich). After staining with anti-CD8
antibodies, the BD Cytoﬁx/Cytoperm Kit (BD Biosciences) was
used for cell ﬁxation and permabilization.
Samples were acquired using LSRII SORP, FACSCanto, or
FACSCelesta instruments (all BD Biosciences) and analyzed using
a DIVA (all BD Biosciences) or FlowJo (version 7.2.5, Tree Star)
software.
T cell inhibition assay
For T cell inhibition assays, CD4+ FOXP3+ (eGFP+) Tregs were
isolated from CRC lesions from Foxp3/eGFP mice and divided into
ST2+ or ST2− cell populations using a FACSAria II cell sorter (BD
Biosciences). As responder cells, CD4+ T cells were MACS-puriﬁed
from spleens of naive St2−/− mice (BALB/c background) using a
CD4+ T Cell Isolation Kit II (Miltenyi Biotec) and labeled with
eFluor670 (Thermo Fisher) following the manufacturer’s instruc-
tions. eFluor670-labeled responder CD4+ T cells (5 × 104) were
either cultured alone or co-cultured with CD4+ FOXP3+ (eGFP+)
ST2+ or ST2− Tregs (2.5 × 104) for 3 days in the presence of 1 μg/
ml anti-CD3 (clone 145-2C11; BD Biosciences). Irradiated spleno-
cytes from naïve St2−/− mice served as antigen-presenting cells
(1.5 × 105). Where indicated, 30 ng/ml rmIL-33 (BioLegend) was
added to the culture.
In vitro Th17 cell differentiation
CD4+ T cells were isolated from spleens of Foxp3/eGFP mice using
the CD4+ T Cell Isolation Kit II (Miltenyi Biotec) according to the
manufacturer’s protocol. CD4+ T cells were divided into eGFP+ or
eGFP− cell populations using a FACSAria II cell sorter (BD
Biosciences). As a control, eGFP− CD4+ T cells (5 × 105) or eGFP+
CD4+ Tregs (1 × 105) were stimulated with 1 μg/ml anti-CD3 (clone
145–2C11; BD Biosciences) and 1 μg/ml anti-CD28 (clone 37.51; BD
Biosciences). To induce Th17 polarization, cells were in addition
incubated with 50 ng/ml recombinant murine (rm) IL-6, 20 ng/ml
rmIL-1β, 100 ng/ml rmIL-21, 20 ng/ml rmIL-23, 2 ng/ml recombi-
nant human TGF-β, 200 ng/ml anti-IL-4, 200 ng/ml anti-IL-2, and
200 ng/ml anti-IFNγ. Where indicated, cells were further cultured
with 10 ng/ml recombinant murine IL-33 (rmIL-33; BioLegend).
Fresh media supplemented with Th17-polarizing cytokines and
rmIL-33 was added on day 3, and cells were analyzed for IL-17A
expression on day 4 (eGFP+ CD4+ Tregs) or on day 5 (eGFP− CD4+
T cells).
Quantitative PCR assay
Mouse colonic tissue was homogenized using a TissueLyser device
(Qiagen). RNA was extracted using TRI-reagent (Sigma-Aldrich) or
an RNeasy Fibrous Tissue Kit (Qiagen). RNA was then reverse-
transcribed into cDNA using an M-MLV Reverse Transcriptase
(Promega) and a mixture of oligo(dT) and random hexamer
primers. For the qPCR reaction, FastStart SYBR Green Master
(Roche Diagnostics) or a Maxima SYBR Green qPCR Master Mix
(Fermentas/Thermo Fisher) were used with commercial primers
speciﬁc for St2 or Il33 (Qiagen). Alternatively, self-designed primers
were used to detect sSt2 (Fwd: 5′-TCG AAA TGA AAG TTC CAG C
A-3′; Rev: 5′-TGT GTG AGG GAC ACT CCT TAC-3′) or Il33 (Fwd: 5′-C
TA CTG CAT GAG ACT CCG TTC TG-3′; Rev: 5′-AGA ATC CCG TGG
ATA GGC AGA G-3′). Reactions were run on a StepOnePlus Real
Time PCR System (Life Technologies/Thermo Fisher) or on an ABI
PRISM Sequence Detection System (Applied Biosystems/Thermo
Fisher). Transcript expression levels were normalized to Gapdh
mRNA, and control versus CRC tissue were compared applying
the 2–ΔΔCT method. Alternatively, expression levels of target genes
were determined with included standard curves for each
individual gene and further normalization to the housekeeping
gene Rps9.
Cytokine measurement in serum and tissues
Protein levels in serum samples from CRC patients or controls
were measured using a commercial ELISA kit for sST2 (R&D
Systems) or by ﬂow cytometry using a bead-based multiplex assay
(LEGENDplexTM human inﬂammation 13-plex panel; BioLegend).
IL-33 in the supernatants of murine colonic explant cultures was
measured by polystyrene bead-based Luminex technology (R&D
Systems) according to the manufacturer’s instructions. A Luminex
200 instrument (Luminex Corporation) was used to run the assay.
Gene expression and pathway analysis
For gene expression analysis, CD4+ FOXP3+ (eGFP+) Tregs were
isolated from CRC lesions form Foxp3/eGFP mice and divided into
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ST2+ or ST2− cell populations using a FACSAria II cell sorter (BD
Biosciences). A total of 0.5–1.5 × 105 ST2+ or ST2− Tregs were
homogenized in RLT buffer (Qiagen) and RNA was isolated with
the RNeasy kit (Qiagen). The quality and integrity of total RNA
were controlled with an Agilent 2100 Bioanalyzer (Agilent
Technologies). Next, 2–10 ng of total RNA were used for biotin
labeling with the GeneChip Pico Kit (Affymetrix). Samples were
hybridized to Clariom™ S chips (Affymetrix) and stained in the
Affymetrix Fluidics Station 450 according to the manufacturer’s
recommendations. Microarrays were scanned with an Affymetrix
GCS 3000 scanner running with Affymetrix GeneChip Command
Console Software (AGCC) and Affymetrix Expression Console™
Software.
RNA microarray data from tumor-isolated ST2+ versus ST2−
CD4+ FOXP3+ (eGFP+) Tregs can be downloaded from the
ArrayExpress Archive of Functional Genomics Data (https://www.
ebi.ac.uk/arrayexpress/experiments/E-MTAB-6842/; name: “Pair-
wise comparison of ST2+ and ST2- FOXP3+ T cells derived from
mouse intestinal tumors”)
For the analysis of differentially expressed pathways, a gene set
enrichment analysis (GSEA) was performed using the SetRank
method.55 This method ﬁrst calculates the p‐value of a gene set
utilizing the ranking of its genes in the ordered list of p‐value as
determined by limma. Next, it discards gene sets that have been
initially ﬂagged as signiﬁcant, if their signiﬁcance is merely due to
the overlap with another gene set. Gene sets were derived from
the following databases: BIOCYC, Gene Ontology, ITFP, KEGG,
LIPID MAPS, PhosphoSitePlus, REACTOME, and WikiPathways.
Supplementary Table 3 shows the data output from the limma
analysis and Supplementary Table 4 provides a list of all pathways
detected by the SetRank method.
Isolation of peripheral blood mononuclear cells from human
donors
Blood samples from CRC patients or healthy donors were collected
in NH4-Heparin Monovette tubes (Sarstedt). PBMCs were isolated
by Ficoll density gradient (Biochrom AG) centrifugation. Isolated
cells were washed with PBS containing 2mmol/l EDTA and 2% FCS
(PAA Laboratories), and cryopreserved in cell culture medium
containing 10% FCS and 10% DMSO (Carl Roth GmbH) until
further analysis.
Patients and healthy donors gave written informed agreement
and analyses of the samples were approved by the Cantonal Ethics
Committee of Bern (2017-01821) or the Ethics Committee of the
Medical Faculty of the University Duisburg Essen (AZ 05-2882).
Histology and immunohistochemistry
Human tissue sections were ﬁxed in 4% formaldehyde and
embedded in parafﬁn. All staining reactions were performed by
automated staining using a BOND RX autostainer (Leica
Biosystems).
For double immunohistochemistry, sections were deparafﬁ-
nized and antigen was retrieved using 1mM Tris solution (pH 9.0)
for 30 min at 95 °C. Sections were stained with goat anti-human IL-
33 (R&D Systems) and mouse anti-human FOXP3 (eBioscience)
primary antibodies, at a dilution of 1:400 and 1:100, respectively.
As secondary antibodies, a rabbit anti-goat (Dako) antibody were
used at a dilution of 1:400. Speciﬁc binding of primary antibodies
was visualized using a polymer-based visualizing system with
horseradish peroxidase as the enzyme and 3,3-diaminobenzidine
(DAB) as a brown chromogen, or an alkaline phosphatase-linked
polymer and Fast Red as red chromogen (Bond™ Polymer Reﬁne
Red Detection), respectively (all from Leica Biosystems). Finally, the
samples were counterstained with haematoxylin and mounted
with Aquatex (Merck). Slides were scanned using a Pannoramic
250 digital scanner (3DHISTECH).
For double immunoﬂuorescence staining, antigen retrieval was
performed using a citrate buffer-based solution (pH 6.0) for 30 min
at 100 °C. Rabbit anti-human ST2 (ABclonal) and mouse
anti-human FOXP3 (eBioscience) were applied as primary anti-
bodies at a dilution of 1:500 or 1:50, respectively. As secondary
antibodies, an Alexa Fluor 488-conjugated goat anti-rabbit (Cell
Signaling Technology) and an Alexa Fluor 555-conjugated goat
anti-mouse (Thermo Fisher) antibody were used, both at a dilution
of 1:1000. Digital pictures were taken using a LSM 700 laser
scanning confocal microscope and an AxioCam MRm digital
camera (both from Zeiss).
Statistical analysis
Results were tested for normal distribution using D'Agostino and
Pearson omnibus normality test. For single comparison of
normally distributed data, two-tailed standard or paired Student’s
t-test was used. For single comparison of not normally distributed
data, Mann–Whitney or Wilcoxon matched-pairs signed rank test
was used. When means of more than two groups were compared,
one-way ANOVA with Dunnett's post-test or Bonferroni post-test,
or two-way ANOVA with Sidak post-test or uncorrected Fisher's
LSD test were used. Statistical analyses were performed using
GraphPad Prism v. 6.03 or v. 7.03 for Windows (Graph-Pad
Software). Unless speciﬁed, only statistically signiﬁcant differences
are indicated in the ﬁgures. For all statistical analyses: * P < 0.05;
**P < 0.01; ***P < 0.001;****P < 0.0001.
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